Lack of dystrophin is associated with deficit of nNOS activity [10,11] and the nNOS-cGMP signaling axis has emerged as a potential therapeutic target in DMD, although the mechanisms downstream of cGMP involved in the pathogenesis of the disease remain unclear. The gene discussed is NOS1; the disease is Duchenne muscular dystrophy.